Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater.
We assessed the proportion of eyes with neovascular age-related macular degeneration (nAMD) in routine clinical practice that reach ≥14 week treatment intervals and their outcomes.We analy...